Cytokinetics (CYTK) Stock Price, Quote & News

Company Profile

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a pot...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 624 3000

Website: www.cytokinetics.com

Address:

350 Oyster Point Boulevard, South San Francisco, United States

Doozio Apr. 20 at 10:01 PM

$CYTK any data due here? Faatch 💣 or a trip ONTO da 🌙

1 · Reply

lukasgx Apr. 17 at 10:12 PM

$CYTK ???? Not normal after hours

2 · Reply

BioTrade2 Apr. 14 at 1:59 AM

$CYTK anyone subscribe to Bio5C discord? Jnap in his podcast said, he sold most of the position. I find it weird since he liked it and wrote a long piece on it. What did he find all of the sudden?

3 · Reply

Doom_Gloom_AR Apr. 13 at 5:33 PM

$CYTK took some may 15 $70 calls 🤙

0 · Reply

ThetaBeatsBeta Apr. 9 at 3:30 PM

$CYTK At the risk of sounding like an idiot, what's driving the incredibly high IV on short dated options? I don't see anything concrete on the calendar. What am I missing?

2 · Reply

Night_Owl_Biotech Apr. 7 at 1:05 AM

Attached is a history of all commercial-stage oncology & non-oncology focused biopharma M&A exits by month & year since 1/1/2017. Our apologies for not tracking both peer groups in the same format It's been hot with DAWN, APLS & SLNO but notice this time the last few years was just as hot. If history is any guide there will be at least 1 or 2 in each peer group by the end of June. $ANAB may be a candidate after announcing the spin-off $GERN has been running but we think there is no universe they sell until after the data read $KALV has been one of the strongest stocks in commercial-stage oncology. It will be 1 year since approval (7/7/25) $MDGL finally? Don't forget fully diluted shares are ~35% higher than traditional $CYTK per a user we respect. This is not investment advice. We're just sharing our calendars for entertainment purposes only.

2 · Reply

erevnon Apr. 6 at 2:28 PM

Barclays maintains Cytokinetics $CYTK at Overweight and raises the price target from $87 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Inarius Apr. 2 at 2:17 PM

$CYTK 12 percent on monthly…lfg!

0 · Reply

timfris Apr. 2 at 2:16 PM

$CYTK still holding shares but f’d up selling a lot around $64 :(

0 · Reply

Machiaveltrade Apr. 1 at 8:23 PM

$CYTK Back in today

0 · Reply

Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Mar 18, 2026, 4:00 PM EDT - 4 weeks ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Mar 16, 2026, 8:00 AM EDT - 5 weeks ago

Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo

Mar 2, 2026, 4:00 PM EST - 7 weeks ago

Cytokinetics to Participate in March Investor Conferences

Feb 24, 2026, 4:00 PM EST - 7 weeks ago

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

Feb 17, 2026, 7:30 AM EST - 2 months ago

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Feb 12, 2026, 4:00 PM EST - 2 months ago

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

Feb 9, 2026, 7:30 AM EST - 2 months ago

Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program

Jan 27, 2026, 7:30 AM EST - 2 months ago

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Jan 22, 2026, 2:39 PM EST - 3 months ago

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors

Jan 20, 2026, 4:00 PM EST - 3 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 5, 2026, 4:00 PM EST - 3 months ago

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 22, 2025, 11:23 AM EST - 4 months ago

Cytokinetics Wins FDA Nod For Heart Drug Myqorzo

Dec 19, 2025, 4:08 PM EST - 4 months ago

US FDA approves Cytokinetics' heart disease drug

Dec 19, 2025, 4:00 PM EST - 4 months ago

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Dec 17, 2025, 7:30 AM EST - 4 months ago

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Dec 12, 2025, 8:42 AM EST - 4 months ago

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Nov 17, 2025, 8:10 AM EST - 5 months ago

Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

Nov 12, 2025, 7:28 PM EST - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Nov 10, 2025, 6:16 PM EST - 5 months ago

CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Nov 10, 2025, 7:30 AM EST - 5 months ago

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Nov 7, 2025, 10:01 AM EST - 5 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Nov 5, 2025, 4:00 PM EST - 5 months ago

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 4:00 PM EST - 5 months ago

Cytokinetics to Participate in November Investor Conferences

Oct 31, 2025, 7:30 AM EDT - 6 months ago

Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Oct 28, 2025, 4:32 PM EDT - 6 months ago

Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments

Oct 28, 2025, 3:08 PM EDT - 6 months ago

Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market

Oct 23, 2025, 1:37 PM EDT - 6 months ago

CYTK INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Oct 22, 2025, 4:00 PM EDT - 6 months ago

Cytokinetics to Announce Third Quarter Results on November 5, 2025

Oct 7, 2025, 7:58 AM EDT - 6 months ago

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

Sep 29, 2025, 4:21 PM EDT - 7 months ago

Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025

Sep 29, 2025, 7:30 AM EDT - 7 months ago

Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025

Sep 25, 2025, 4:32 PM EDT - 7 months ago

Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately

Doozio Apr. 20 at 10:01 PM

$CYTK any data due here? Faatch 💣 or a trip ONTO da 🌙

1 · Reply

lukasgx Apr. 17 at 10:12 PM

$CYTK ???? Not normal after hours

2 · Reply

BioTrade2 Apr. 14 at 1:59 AM

$CYTK anyone subscribe to Bio5C discord? Jnap in his podcast said, he sold most of the position. I find it weird since he liked it and wrote a long piece on it. What did he find all of the sudden?

3 · Reply

Doom_Gloom_AR Apr. 13 at 5:33 PM

$CYTK took some may 15 $70 calls 🤙

0 · Reply

ThetaBeatsBeta Apr. 9 at 3:30 PM

$CYTK At the risk of sounding like an idiot, what's driving the incredibly high IV on short dated options? I don't see anything concrete on the calendar. What am I missing?

2 · Reply

Night_Owl_Biotech Apr. 7 at 1:05 AM

2 · Reply

erevnon Apr. 6 at 2:28 PM

Barclays maintains Cytokinetics $CYTK at Overweight and raises the price target from $87 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Inarius Apr. 2 at 2:17 PM

$CYTK 12 percent on monthly…lfg!

0 · Reply

timfris Apr. 2 at 2:16 PM

$CYTK still holding shares but f’d up selling a lot around $64 :(

0 · Reply

Machiaveltrade Apr. 1 at 8:23 PM

$CYTK Back in today

0 · Reply

Quantumup Apr. 1 at 1:46 PM

Evercore ISI reiterated $CYTK Outperform; $80 $EWTX $BMY TNYA Here's what Evercore ISI said in its note to investors: https://x.com/Quantumup1/status/2039337667427459156?s=20

0 · Reply

WAJeff Mar. 31 at 2:07 PM

$CYTK Shares sold at $67 for 10.6% gain. This has been stuck in a channel since October.

0 · Reply

armedgemini Mar. 31 at 10:05 AM

$CYTK Analysts have been saying downside is up to -40% while upside is 50% if all endpoints are met. Doesn’t sound like a great risk reward for buying shares and options IV seems to just be inching up until results are released. I may go long a couple covered calls or cash scores puts when they give a firm date. Options market is predicting it will be released before end of May.

1 · Reply

SuperGreenToday Mar. 27 at 7:33 PM

$CYTK Share Price: $62.80 Contract Selected: Jul 17, 2026 $65 Calls Buy Zone: $11.98 – $14.80 Target Zone: $20.66 – $25.25 Potential Upside: 63% ROI Time to Expiration: 111 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

timfris Mar. 27 at 3:20 PM

$MDGL let’s have a buyout Monday. Here, $CYTK, $RVMD, or $VKTX.

1 · Reply

biolover Mar. 26 at 7:13 PM

$CYTK $MDGL $VKTX $LLY could acquires CYTK. No way on earth mdgl. But if any BP acquires mdgl. Vk 2808 will be worth billions.

1 · Reply

timfris Mar. 26 at 7:09 PM

$VKTX gonna be a big buyout somewhere. Huge spike in $MDGL and $CYTK also. I think someone got word on a big deal but not sure which one.

1 · Reply

erevnon Mar. 17 at 6:46 PM

JP Morgan maintains Cytokinetics $CYTK at Overweight and raises the price target from $74 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Quantumup Mar. 17 at 1:20 PM

JPMorgan⬆️ $EWTX's PT to $45 from $34, plus added to the 'Analyst Focus List,' while reiterating at an Overweight rating, and said that remains +VE on shares in anticipation of a # of catalyst across the Co's pipeline. $CYTK $BMY $CAPR Here's what JPMorgan had to say:::For 2026, we continue to remain positive on EWTX in anticipation of a number of catalysts across the pipeline, particularly renewed interest in EDG-7500, a novel, or al cardiac sarcomere modulator and the broader cardiovascular/hypertrophic cardiomyopathy (HCM) space. Recall, EDG-7500 does not bind to the myosin motor head and instead indirectly regulates myosin by targeting complex sarcomere protein-protein interactions that control contraction and relaxation processes. JPMorgan also said—the full 12 week data in Q2 will be meaningful for the fundamental view on EDG-7500—it increasingly likes the setup for Edgewise in 2026.

1 · Reply

Quantumup Mar. 17 at 12:45 PM

Cantor🏁 $TENX and said it sees 2-3X move if LEVEL hits Stat Sig and cut in ½ or worse on failure. $TECX $MRK $BAYRY - AZN LLY $CYTK Cantor said::We are initiating coverage of Tenax Therapeutics (TENX) with an Overweight rating and a $35 price ahead the pivotal LEVEL Phase 3 readout of TNX-103 (oral levosimendan) in PH-HFpEF expected in 3Q26. TENX is still relatively under the radar with a ~$1B fully diluted market cap, despite having a Phase 3 readout in PH-HFpEF coming in 3Q26. If LEVEL hits and is stat sig (p<0.05), we think the stock could move 2-3x. This is a high-risk, high-reward setup into the data. The setup cuts both ways: if LEVEL fails, the stock could get cut in half (or worse).

0 · Reply

Quantumup Mar. 17 at 11:33 AM

JPMorgan⬆️ $CYTK's PT to $75 from $74, plus added to its 'Analyst Focus List' and placed on a "Positive Catalyst Watch," while reiterating at an Overweight rating. $EWTX $BMY TNYA Here's what JPMorgan had to say::We view CYTK's near-term outlook as favorable, especially on the heels of the recent approval of Myqorzo (aficamten) for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), with early signs in the marketplace appearing strong. That said, we think we may be on the precipice of non-obstructive hypertrophic cardiomyopathy (nHCM) data milestones that could be transformative for the Myqorzo launch and could significantly expand/broaden the market for the product (the company estimates that there are conservatively ~100k nHCM patients that could be eligible patients today).

0 · Reply

Quantumup Mar. 17 at 10:10 AM

Stifel reiterated $CYTK Buy; $98, and said::We're reiterating our Buy rating on CYTK ahead of the big 2Q ACACIA readout where we think the trial likely works (POS 70%). $BMY $EWTX $TNYA Here's what else Stifel had to say:: https://x.com/Quantumup1/status/2033847804846576074?s=20

0 · Reply

Market Cap	8.22B
Revenue (ttm)	88.04M
Net Income (ttm)	-784.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-891.59%
Debt to Equity Ratio	-0.44

Volume	1,027,400
Avg Vol	1,930,378
Day's Range	N/A - N/A
Shares Out	123.16M
Stochastic %K	70%
Beta	0.47
Analysts	Strong Sell
Price Target	$93.31